Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pepinemab - Vaccinex

Drug Profile

Pepinemab - Vaccinex

Alternative Names: moAb VX15/2503; VX 15; VX 15/2503

Latest Information Update: 05 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaccinex
  • Developer Bristol-Myers Squibb; Children's Oncology Group; Emory University; Merck KGaA; National Cancer Institute (USA); Teva Pharmaceutical Industries; UCLAs Jonsson Comprehensive Cancer Center; Vaccinex
  • Class Antibodies; Antidementias; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD100 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Huntington's disease

Highest Development Phases

  • Phase II Huntington's disease
  • Phase I/II Adenocarcinoma; Alzheimer's disease; Non-small cell lung cancer; Osteosarcoma; Solid tumours; Squamous cell cancer
  • Phase I HER2 positive breast cancer
  • No development reported Colorectal cancer; Malignant melanoma; Multiple sclerosis; Pancreatic cancer

Most Recent Events

  • 05 Oct 2023 Vaccinex plans phase-III trial for Huntington’s disease
  • 27 Sep 2023 Efficacy and adverse events data from phase-I/II trial in Pancreatic cancer released by Vaccinex
  • 26 Sep 2023 Interim efficacy data from a phase I/II KEYNOTE-B84 trial in Squamous cell cancer released by Vaccinex
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top